RxDoctor Payments Data

Uma Choday, MD

Psychiatry · Boca Raton, FLNPI 1114084613

Payments from drug & device makers

$2,371in general payments, 2019–2025

Across 96 payments — averaging $24.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Corium, LLC$599
  • Neuronetics, Inc.$522
  • Ironshore Pharmaceuticals Inc.$189
  • Neurocrine Biosciences, Inc.$175
  • Takeda Pharmaceuticals U.S.A., Inc.$170
  • Neos Therapeutics, LP$152
  • plus $564 from 12 others

What the payments were for

  • Food & beverage$2,371100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,371 in reported general payments places this provider in the 70th percentile of 2,059 psychiatry providers in Florida.

See all psychiatry providers in Florida

Medicare billing

Part B allowed, 2024
$32,942
Medicare patients
36
Services billed
356

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AtivanLorazepam13$31,732
Aripiprazole68$6,615
RisperdalRisperidone11$4,056
Clonazepam212$1,393
Duloxetine Hcl124$1,352
Quetiapine Fumarate104$1,310
Olanzapine47$1,290
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine49$1,263
Buspirone Hcl119$1,212
Trazodone Hcl157$884
Oxcarbazepine16$863
Atomoxetine Hcl12$826
Escitalopram Oxalate105$729
Bupropion XlBupropion Hcl42$687
Fluoxetine Hcl92$626

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonRisperdal$63$4,05611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,059 psychiatry providers in Florida.

Other psychiatry in Boca Raton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →